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Despite a benign histologic appearance, thymomas have metastatic
potential. Here we report a case of a patient with a Masaoka stage
IVb thymoma who was successfully treated using a multimodal
strategy including systemic chemotherapy, radiofrequency ablation,
and thoracic surgery. Despite complete remission after treatment,
the patient developed myasthenia gravis with ptosis and neck drop
symptoms. Hepatic meastasis of thymoma is a relatively rare occur-
rence and, to the best of our knowledge, this is the first report about
the application of radiofrequency ablation to thymoma.
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CASE REPORT
A 54-year-old Japanese woman presented with left arm
edema and venous dilatation in the anterior chest wall and left
cervical region. Radiologic examinations at another hospital
revealed a large tumor in the anterior mediastinum with
occlusion of the left brachiocephalic vein and multiple liver
nodules (Figures 1A, B). Needle biopsy specimen analysis
from mediatinum demonstrated that the tumor was a thy-
moma of World Health Organization classification type AB
(a tumor comprised of a homogenous population of neoplas-
tic epithelial cells with spindle/oval shape, lacking nuclear
atypia accompanied by foci rich in lymphocytes) or B2 (a tumor
in which the neoplastic epithelial component appears as scat-
tered plump cells with vesicular nuclei and distinct nucleoli
among a heavy population of lymphocytes) (Figure 2A), and
Masaoka classification stage IVb. She was admitted to Osaka
Saiseikai Senri Hospital for treatment. On admission, her serum
acetylcholine receptor (AchR) antibody concentration margin-
ally elevated to 1.7 nmol/ml (0.2 nmol/ml). The tumor dra-
matically regressed after 4 cycles of systemic chemotherapy
with cisplatin and etoposide (VP-16) (Figures 1C, D). A liver
tumor biopsy showed histologic evidence for thymoma metas-
tasis (Figure 2B), and the only one residual hepatic nodule after
chemotherapy was treated with radiofrequency ablation (RFA).
A follow-up positron emission tomography (PET)-computed
tomography scan revealed an uptake exclusively in anterior
mediastinal residual tumor, suggesting that tumor resection
would result in complete disease remission (Figures 3A, B).
Therefore, extended thymectomy with complete tumor resection
was performed and the resected specimens were histologically
certified as type B2 thymomas.
Two days postsurgery, the patient suddenly developed
myasthenia gravis (MG) which was confirmed by an edro-
phonium chloride test, and the patient completely recovered
by administration of pyridostigmine at the doses of 180 mg/d.
The serum AchR antibody concentration gradually increased
to 22.2 nmol/ml just before surgery, when MG symptoms
were not obvious. After hospital discharge, the patient visited
a psychiatrist of her own free will for disease-related anxiety
and was prescribed some psychiatric agents. Forty-two days
postsurgery, MG recurred, possibly exacerbated by these
antianxiety medications. MG symptoms such as ptosis, neck
drop, and speech disturbance were still present despite dis-
continuing those medications. Although the thymus had been
totally removed, the serum AchR antibody concentration
increased to 46.0 nmol/ml.
Apart from the unexpected MG emergence, all meta-
static and potentially malignant thymomas were completely
removed. Continued disease-free recovery with prolonged
survival was expected. Although this patient is alive 7 months
after surgery, long term follow up is needed.
DISCUSSION
Among advanced-stage thymoma patients, surgical
resection is generally contraindicated for Masaoka stage
IVb, whereas stage IVa is often treated with multimodal
therapy including surgery. In Masaoka stage IVb thymo-
mas, hepatic metastasis is a relatively rare condition.1
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Although these tumors are generally considered to be
nonresectable, here we report a case of thymoma accom-
panied by hepatic metastasis that was successfully treated
with multimodal therapy. According to Masaoka clinical
staging and several reports, the long-term survival of stage
IV thymoma patients is disappointing compared with ear-
lier stages.2 In the largest published cohort study, the
respective 5-year survival rates for stage IVa and IVb
thymomas were 70.6% and 52.8%, and were significantly
shorter than those of the earlier stages (100.0%, 98.4%,
and 88.7% for stage I, II and III, respectively).3 Kondo
et al. also reported that the respective 5-year survival rates
of total resection, subtotal resection, and inoperable thy-
moma groups were 93%, 64%, and 36%, suggesting that
tumor resectability is an important factor in determining
survival.3 Several reports have supported the survival
benefit in resections of recurrences or distant metastases in
thymoma patients.1,4 According to these data, aggressive
multidisciplinary treatment may contribute to prolonging
the survival of stage IVb thymoma.
Fluorodeoxyglucose-PET imaging is a valuable tool for
clarifying thymoma location or disease recurrence.5,6 In our
case, fluorodeoxyglucose-PET revealed a preoperative medi-
astinal tumor with a high uptake value and a post-RFA
metastatic lesion without uptake. Thus, extended thymectomy
was considered to result in complete remission.
FIGURE 1. Chest (A) and abdominal
(B) CT showing large tumors in the
anterior mediastinum and in the liver
before treatment. After chemother-
apy, these tumors dramatically re-
gressed both in the mediastinum (C)
and in the liver (D).
FIGURE 2. The biopsy specimens from anterior
mediastinum (A, HE stain, original 400), and
from liver after 2 cycles of systemic chemother-
apy (B, original 400). They were rich in nonma-
lignant, rounded nuclear lymphocytes with po-
lygonal epithelial cells corresponding to type B2
thymoma in WHO Classification.
FIGURE 3. PET-CT examination after chemo-
therapy and RFA. Tumor activity was revealed
in the anterior mediastinum (A), but not in the
liver (B).
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We used RFA to eliminate the hepatic metastatic lesion
instead of hepatectomy. Although complete remission was
achieved, stage IVb thymoma may recur in the future. The
damage to normal liver parenchyma is minimal by RFA
treatment and repeated applications of RFA should be toler-
able if future recurrences appear in the liver.
In patients without preoperative MG, a small propor-
tion develop MG after complete removal of thymoma with
the rare incidences ranging 0.97 to 3.3%.7 Kondo et al.
showed that the frequency of postoperative MG is higher
in patients who have undergone thymectomy and extended
thymectomy (0.7–3.9%) than in patients who have under-
gone selective tumor resection (0.0 –2.8%), suggesting that
complete resection of the thymus gland does not prevent
postoperative MG. On the other hand, they showed that the
improvement rate of postoperative MG treated with anti-
cholinesterase compounds and/or steroids was almost
equal to or better than MG with preresected thymoma and
MG without thymoma. In addition, the prognosis is rela-
tively favorable in thymoma treated with total thymec-
tomy. This implies that thymectomy or extended thymec-
tomy is recommended over simple tumor resection, even
though thymectomy is associated with the frequency of
postoperative MG.7–9 Because it is widely accepted that at
least 1 year is needed for apparent improvement of MG by
thymectomy, MG symptoms in such patients may improve
after months or years from extended thymectomy.10 Fur-
thermore, careful follow-up of both thymoma and MG
should be done in these patients.
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ERRATUM
The Journal of Thoracic Oncology regrets an error in the article, “HOXB2 as a novel prognostic indicator for stage I lung
adenocarcinoma” in the September issue of J. Thorac. Oncol. (vol. 2, number 9, 2007). Yuichi Ishikawa, MD, PhD, was
not listed.
The author listing should have appeared as:
Kentaro Inamura, MD, PhD, Yuki Togashi, MPharm, Michiyo Okui, PhD, Hironori Ninomiya, MD, Miyako Hiramatsu,
MD, Yukitoshi Satoh, MD, PhD, Sakae Okumura, MD, Ken Nakagawa, MD, Takashi Shimoji, MD, PhD, Tetsuo Noda,
MD, PhD, and Yuichi Ishikawa, MD, PhD.
The affiliation printed for Tetsuo Noda was also wrong. Dr. Noda belongs to Genome Center, Japanese Foundation for
Cancer Research (JFCR). The last author, Yuichi Ishikawa, belongs to the Department of Pathology, The Cancer Institute.
We regret any confusion or inconvenience this may have caused, and have corrected the articles as published on jto.org.
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